文献速递神经肌肉病

高热量营养对肌萎缩侧索硬化生存的影响

Effect of High-Caloric Nutrition on Survival in Amyotrophic Lateral Sclerosis.
PubMed 文献 · Ann Neurol · 2020-01-06

LIPCAL-ALS 研究是一项在德国12个中心开展的1:1随机、安慰剂对照、平行组、双盲试验,2015年2月至2018年9月纳入201例肌萎缩侧索硬化患者,在利鲁唑100mg/日基础上比较高热量脂肪饮食(405kcal/日,100%脂肪)与安慰剂的生存获益。主要终点生存分析显示两组28个月生存概率分别为0.37与0.39,风险比0.97(单侧97.5%CI -∞至1.44,p=0.44),全人群未见延长生存的证据;事后分析提示快速进展亚组可能获益。

要点

  • 全人群分析未显示高热量脂肪饮食延长ALS患者生存。
  • 快速进展亚组的事后分析提示可能存在的生存获益,需谨慎解读。
  • 研究在利鲁唑治疗基础上叠加高热量脂肪饮食干预。

核心结论

  • 高热量脂肪饮食对整体肌萎缩侧索硬化人群未显示延长生存的效果。
  • 事后分析显示快速进展亚组可能存在生存获益,但属于探索性结果。

研究设计与样本

  • 1:1随机、安慰剂对照、平行组、双盲试验(LIPCAL-ALS研究),2015年2月至2018年9月在德国12个ALS/MND-NET中心开展。
  • 纳入201例患者(女性80例、男性121例,年龄62.4±10.8岁),随机接受高热量脂肪饮食(405kcal/日,100%脂肪)或安慰剂,均联合利鲁唑100mg/日。
  • 随机化后在第3、6、9、12、15、18个月进行随访。

主要发现

  • 主要终点生存分析显示,28个月(末次事件时点)生存概率在安慰剂组为0.39(95%CI 0.27-0.51),在高热量脂肪饮食组为0.37(95%CI 0.25-0.49)。
  • 风险比为0.97(单侧97.5%CI -∞至1.44,p=0.44)。
  • 事后分析显示快速进展亚组存在显著的生存获益。

临床怎么用

  • 不应基于本研究结果对整体ALS人群常规推荐高热量脂肪饮食以延长生存。
  • 对快速进展患者是否可从高热量脂肪饮食获益,需结合事后分析结果个体化评估并进一步验证。

局限性

  • 快速进展亚组的生存获益来自事后分析,并非预设主要分析,证据强度有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Weight loss has been identified as a negative prognostic factor in amyotrophic lateral sclerosis, but there is no evidence regarding whether a high-caloric diet increases survival. Therefore, we sought to evaluate the efficacy of a high-caloric fatty diet (HCFD) for increasing survival. METHODS: A 1:1 randomized, placebo-controlled, parallel-group, double-blinded trial (LIPCAL-ALS study) was conducted between February 2015 and September 2018. Patients were followed up at 3, 6, 9, 12, 15, and 18 months after randomization. The study was performed at 12 sites of the clinical and scientific network of German motor neuron disease centers (ALS/MND-NET). Eligible patients were randomly assigned (1:1) to receive either HCFD (405kcal/day, 100% fat) or placebo in addition to riluzole (100mg/day). The primary endpoint was survival time, defined as time to death or time to study cutoff date. RESULTS: Two hundred one patients (80 female, 121 male, age = 62.4 ± 10.8 years) were included. The confirmatory analysis of the primary outcome survival showed a survival probability of 0.39 (95% confidence interval [CI] = 0.27-0.51) in the placebo group and 0.37 (95% CI = 0.25-0.49) in the HCFD group, both after 28 months (point in time of the last event). The hazard ratio was 0.97, 1-sided 97.5% CI = -∞ to 1.44, p = 0.44. INTERPRETATION: The results provide no evidence for a life-prolonging effect of HCFD for the whole amyotrophic lateral sclerosis population. However, post hoc analysis revealed a significant survival benefit for the subgroup of fast-progressing patients. ANN NEUROL 2020;87:206-216.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Ludolph AC, Dorst J, Dreyhaupt J, et al. Effect of High-Caloric Nutrition on Survival in Amyotrophic Lateral Sclerosis. Ann Neurol. 2020. PMID: 31849093. doi:10.1002/ana.25661

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。